No longer trading

Acquired by Chiesi Farmaceutici S.p.A.

The acquisition closed on June 11, 2026 (SEC 8-K 2.01). Its last closing price was on June 10, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 27, 2026. Source: SEC 8-K 2.01

KALV

KalVista Pharmaceuticals, Inc. KALV

NasdaqSmall CapHealthcare

Final 13F Pro quality score

Final rank #2,781 of 2,854 · as of May 27, 2026

Why it scores 13Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$40.86M

Quarter to Mar 31

Net income

$-23.49M

Quarter to Mar 31

Free cash flow

$-14.58M

Quarter to Mar 31

Operating margin

-57.4%

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026
$189 total
IFP Advisors, Inc
$189New
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2026
EDGAR

Net Income

Q4 2026
EDGAR

EPS (Diluted)

Q4 2026
EDGAR

Operating Margin

Q4 2026
EDGAR

ROIC

Q4 2026
EDGAR

Free Cash Flow

Q4 2026
EDGAR

Debt/Equity

Q4 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KALV

Earnings Per Share

13fpro.ai/company/KALV

Loading ratio trend…

KALV insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in KALV

1 transaction in KALV reported by 1 member of Congress under the STOCK Act, most recent trade Dec 12, 2022. Reported transactions, not recommendations.

All Congress stock trades →

About KalVista Pharmaceuticals, Inc. (KALV): stock profile, AI score and financials

Acquired by Chiesi Farmaceutici S.p.A.: KalVista Pharmaceuticals, Inc. (KALV) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on June 11, 2026 (SEC 8-K 2.01). Its last closing price was on June 10, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 27, 2026. KalVista Pharmaceuticals, Inc. (KALV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks KALV using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q4 2026), KalVista Pharmaceuticals, Inc. reports quarterly revenue of $40.9M, net income of $-23.5M, an operating margin of -57.4%. KALV trades on the Nasdaq exchange and files with the SEC under CIK 1348911. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KALV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KalVista Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1348911 →